Parkinson's disease

Parkinson's disease

Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning

Developing disease-modifying drugs for neurodegenerative diseases has been very challenging. Now a machine learning approach has been used to identify small molecule inhibitors of α-synuclein aggregation, a process implicated in Parkinson’s disease.

This groundbreaking discovery opens up new possibilities for the development of effective treatments for Parkinson's disease, offering hope to millions of people worldwide who are affected by this debilitating condition. By targeting the underlying cause of the disease, these inhibitors have the potential to slow down or even halt its progression, improving the quality of life for patients and their families.